商品编号


AG-40T-0527-C100



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

100 ?g

商品信息


More Information



Product Details



Synonyms

Ubiquitin-conjugating Enzyme Variant 1a; CIR1; CROC1; TRAF6-regulated IKK Activator 1 β Uev1A; Mms2; UBE2V1



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human Uev1a (Accession Nr. Q13404) fused to a N-terminal His-tag.



Crossreactivity

Human



Formulation

Liquid. In 50mM HEPES pH 7.5, 200mM NaCl, 10% Glycerol (v/v), 1mM TCEP.



Other Product Data


Use:
Member of the ubiquitin?conjugating (E2) enzyme family that receives ubiquitin from a ubiquitin?activating (E1) enzyme and subsequently interacts with a ubiquitin ligase (E3) to conjugate ubiquitin to substrate proteins. Reaction conditions will need to be optimized for each specific application. We recommend an initial protein concentration of 0.1-?1μM.



Declaration

Manufactured by Boston Biochem



Shipping and Handling



Shipping

DRY ICE



Short Term Storage

-20°C



Long Term Storage

-80°C



Handling Advice

Aliquot to avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -80°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Ubiquitin-conjugating Enzyme Variant 1a (Uev1a), also known as ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), is a member of the ubiquitin-conjugating (E2) enzyme family. Human Uev1a/UBE2V1 and its mouse ortholog have predicted molecular weights of 19 kDa and 16.5 kDa, respectively. The human protein shares 89% amino acid (aa) sequence identity with its mouse ortholog. The E2 catalytic core domain of Uev1a/UBE2V1 lacks an active site cysteine residue, rendering it catalytically inactive on its own. However, in the cytoplasm Uev1a/UBE2V1 is able to form a catalytically active complex with UBE2N/Ubc13, which mediates the synthesis Lys63-linked ubiquitin chains and is required for NF-κB activation. Uev1a/UBE2V1 is required for UBE2N (Ubc13)/Uev1a Complex-dependent Lys63-linked ubiquitin chain formation. More specifically, Uev1a/UBE2V1 orients the ubiquitin molecule to favor linkage at Lys63 via a non-covalent interaction with the ubiquitin molecule. The human protein contains a non-conserved 30 aa N-terminal tail that functionally differentiates it from Mms2, another E2 enzyme variant and UBE2N/Ubc13 binding partner. Pharmacological inhibition of the UBE2N (Ubc13)/Uev1a complex blocks the proliferation of diffuse large B-cell lymphoma cells, suggesting that this complex may play a role in cancer.